Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6391262 | 1.00 | TDP1 (0.41) | TDP1CA9CA1CA2CA4 | |
| SCHEMBL49343 | 0.96 | TDP1 (0.44) | TDP1CA9CA1CA2CA4 | |
| Benzene SCHEMBL28239903 | 0.96 | TDP1 (0.44) | TDP1CA9CA1CA2CA4 | |
| SCHEMBL28047489 | 0.96 | TDP1 (0.44) | TDP1CA9CA1CA2CA4 | |
| Benzene SCHEMBL4445625 | 0.96 | TDP1 (0.44) | TDP1CA9CA1CA2CA4 | |
| Benzene SCHEMBL28943358 | 0.96 | TDP1 (0.44) | TDP1CA9CA1CA2CA4 | |
| Ammonia Solution, Strong SCHEMBL23797888 | 0.92 | TDP1 (0.41) | TDP1CA9CA1CA2CA4 | |
| Hydrogen Sulfide SCHEMBL1157712 | 0.92 | TDP1 (0.41) | TDP1CA9CA1CA2CA4 | |
| SCHEMBL9542822 | 0.92 | TDP1 (0.41) | TDP1CA9CA1CA2CA4 | |
| SCHEMBL21597051 | 0.92 | TDP1 (0.41) | TDP1CA9CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114480534-B | Protein semisynthesis by chemoenzymatic methods based on transpeptidase | 清华大学 | 2024-02-13 | — | — | CN | claimed |
| CN-114195902-B | Recombinant protein structural domain enhanced TET enzyme and whole genome DNA methylation detection method | 翌圣生物科技(上海)股份有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-114591440-B | Recombinant TET enzyme MBD4-NgTET1 and application thereof in improving 5caC (cubic-alternating current) ratio in TET enzyme oxidation product | 翌圣生物科技(上海)股份有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-114591439-B | Recombinant TET enzyme MBD2-NgTET1 and application thereof in improving 5caC (cubic-alternating current) ratio in TET enzyme oxidation product | 翌圣生物科技(上海)股份有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-114591441-B | Recombinant TET enzyme MBD3-NgTET1 and application thereof in improving 5caC (cubic-alternating current) ratio in TET enzyme oxidation product | 翌圣生物科技(上海)股份有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-114591441-A | Recombinant TET enzyme MBD3-NgTET1 and application thereof in improving proportion of 5caC in TET enzyme oxidation product | 翌圣生物科技(上海)股份有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-114591440-A | Recombinant TET enzyme MBD4-NgTET1 and application thereof in improving proportion of 5caC in TET enzyme oxidation product | 翌圣生物科技(上海)股份有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-114591439-A | Recombinant TET enzyme MBD2-NgTET1 and application thereof in improving proportion of 5caC in TET enzyme oxidation product | 翌圣生物科技(上海)股份有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-114480534-A | Protein semi-synthesis based on chemical enzymatic methods of transpeptidase | 清华大学 | 2022-05-13 | — | — | CN | claimed |
| CN-114195902-A | Recombinant protein domain enhanced TET enzyme and whole genome DNA methylation detection method | 翌圣生物科技(上海)股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-20200113929-A1 | SOLUBLE ADDUCTS OF BORIC ACID OR DERIVATIVES AND PRECURSORS THEREOF WITH CHITOSAN OLIGOSACCHARIDE DERIVATIVES | BIOPOLIFE SRL (75% ownership) (IT) | 2020-04-16 | — | — | US | claimed |
| EP-3559106-A1 | SOLUBLE ADDUCTS OF BORIC ACID OR DERIVATIVES AND PRECURSORS THEREOF WITH CHITOSAN OLIGOSACCHARIDE DERIVATIVES | Biopolife Srl (IT) | 2019-10-30 | — | — | EP | claimed |
| US-10427982-B2 | Method of carbon coating on nanoparticle and carbon coated nanoparticle produced by the same | KOREA INSTITUTE OF ENERGY RESEARCH (KR) | 2019-10-01 | — | — | US | claimed |
| WO-2018116224-A1 | SOLUBLE ADDUCTS OF BORIC ACID OR DERIVATIVES AND PRECURSORS THEREOF WITH CHITOSAN OLIGOSACCHARIDE DERIVATIVES | BIOPOLIFE SRL (IT) | 2018-06-28 | — | — | WO | claimed |
| US-20170081248-A1 | METHOD OF CARBON COATING ON NANOPARTICLE AND CARBON COATED NANOPARTICLE PRODUCED BY THE SAME | KOREA INSTITUTE OF ENERGY RESEARCH (KR) | 2017-03-23 | — | — | US | claimed |
| EP-3144277-A1 | METHOD OF CARBON COATING ON NANOPARTICLE AND CARBON COATED NANOPARTICLE PRODUCED BY THE SAME | Korea Institute of Energy Research (KR) | 2017-03-22 | — | — | EP | claimed |
| EP-1899317-A2 | ENANTIOMERS OF N,N-DIMETHYL-3-(2-THIENYL)-3-HYDROXYPROPANAMINE BORANE AS INTERMEDIATES IN THE SYNTHESIS OF DULOXETINE | Teva Pharmaceutical Industries Ltd (IL) | 2008-03-19 | — | — | EP | claimed |
| US-20080015362-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | TEVA PHARMACEUTICALS USA, INC. | 2008-01-17 | — | — | US | claimed |
| WO-2007123900-A2 | ENANTIOMERS OF N,N-DIMETHYL-3-(2-THIENYL)-3-HYDROXYPROPANAMINE BORANE AS INTERMEDIATES IN THE SYNTHESIS OF DULOXETINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-01 | — | — | WO | claimed |
| US-20050173254-A1 | Nickel cobalt boron ternary alloys | TASKEM, INC. | 2005-08-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015362-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | HTR3A, PNMT, TPH1 | TDP1 932/4885CA9 4200/4885CA1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.